Levosimendan Eql Pharma

Levosimendan, the active ingredient in Levosimendan Eql Pharma, is a calcium sensitizer (inodilator) presented as an injectable solution for intravenous use. It treats acute decompensated heart failure, cardiogenic shock (off‑label) and is used as adjunctive therapy in cardiac surgery. GNH USA supplies Levosimendan Eql Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide.

Levosimendan is employed in the management of severe cardiac conditions where enhanced contractility and vasodilation are required. Acute decompensated heart failure: improves cardiac output and reduces congestion. Cardiogenic shock (off‑label): provides inotropic support while lowering afterload. Adjunctive therapy in cardiac surgery: stabilises haemodynamics during the peri‑operative period.

Levosimendan may cause a range of adverse reactions that clinicians monitor during therapy.

Common Side Effects: - Hypotension: drop in blood pressure, especially during rapid infusion. - Headache: mild to moderate intensity. - Nausea or vomiting: gastrointestinal discomfort. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Arrhythmias: ventricular or atrial ectopic beats. - Myocardial ischaemia: reduced coronary perfusion. - Severe hypotension: refractory low blood pressure. - Allergic reactions: rash, bronchospasm, or anaphylaxis.

Levosimendan requires careful clinical monitoring and patient assessment before and during administration. - Cardiovascular monitoring: continuous blood pressure and ECG observation throughout infusion. - Renal function: evaluate renal status prior to use and adjust therapy as needed. - Electrolyte balance: correct hypokalaemia and hypomagnesemia before initiation. - Concomitant vasodilators: avoid high‑dose nitrates to prevent profound hypotension. - Pregnancy and lactation: use only if potential benefits outweigh uncertain risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with several cardiovascular agents, necessitating vigilance.

Major Interactions (Avoid): - Sodium nitroprusside: additive vasodilation may cause severe hypotension. - Beta‑blockers: may blunt the desired inotropic effect. - Calcium channel blockers: increase risk of arrhythmias.

Moderate Interactions (Monitor Closely): - Diuretics: may exacerbate electrolyte disturbances. - ACE inhibitors or ARBs: monitor blood pressure for additive hypotensive effect. - Other inotropes (e.g., dobutamine): adjust dosing to avoid excessive cardiac stimulation.